Ambrisentan

Type: Keyphrase

Name: Ambrisentan

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Drug Worsens Idiopathic Pulmonary Fibrosis

Patients with idiopathic pulmonary fibrosis (IPF) who received ambrisentan are more likely to have their disease worsen and to require hospitalization than those who received placebo, new research suggests.While the cause of IPF is not yet known, but ... [Published RT Magazine - May 15 2013]

Entities: Ambrisentan, disease progression, Placebo, Drugs, endothelin receptor antagonist

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Ambrisentan Fails in Lung Fibrosis

A Phase III trial has shown that ambrisentan actually induces progression of idiopathic pulmonary fibrosis. Medpage Today Full Issue ... [Published FDA News - May 08 2013]

Entities: Ambrisentan, fibrosis, Phase III

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Ambrisentan not effective in idiopathic pulmonary fibrosis

The endothelin A receptor-selective antagonist ambrisentan is not effective for reducing the rate of idiopathic pulmonary fibrosis progression, according to a study published in the May 7 issue of the Annals of Internal Medicine.(HealthDay)—The endothelin ... [Published Medical Xpress - May 08 2013]

Entities: Ambrisentan, Patient, disease progression, Internal Medicine, Placebo

First reported May 06 2013 - Updated May 07 2013 - 2 reports

Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan A Parallel, Randomized Trial

Chinese translation Background: Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung fibroblast proliferation and contractile activity via the endothelin A (ET A ) receptor. ... [Published Annals of Internal Medicine - May 07 2013]

Entities: Ambrisentan, Idiopathic Pulmonary Fibrosis, Patient

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Issue Summary May 7, 2013

issue, including articles on ambrisentan treatment for idiopathic pulmonary fibrosis, a new lung transplant allocation score, HIV and hepatitis C virus-associated liver disease, smoking cessation in patients with suspected tuberculosis, and management ... [Published Annals of Internal Medicine - May 07 2013]

Entities: Ambrisentan, U.S. Preventive Services Task Force, asymptomatic, Smoking Cessation

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Ambrisentan Fails in Lung Fibrosis

This randomized, controlled trial of ambrisentan for idiopathic pulmonary fibrosis was terminated early due to a low probability of demonstrating efficacy at full enrollment.Be aware that the analysis at 75% of targeted recruitment demonstrated worse ... [Published MedPage Today - May 06 2013]

Entities: Ambrisentan, Placebo, Pulmonary Hypertension, disease progression, fibrosis

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Opinion/decision on a Paediatric Investigation Plan (PIP): Volibris, Ambrisentan, Therapeutic area: Cardiovascular diseases

[Published Opinion/decision on a Paediatric Investigation ... - May 03 2013]

Entities: Ambrisentan, Cardiovascular Disease, Investigation

First reported Apr 27 2013 - Updated Apr 27 2013 - 1 reports

Parliamentary panel comes down hard on health ministry

A parliamentary committee has assailed the health ministry for failing to take substantive action based on the panel's findings of irregularities in the way the country's drug regulator functions.Terming the ministry's so-called Action Taken Report "vague, ... [Published Individual.com - Apr 27 2013]

Entities: Drugs, Clinical trials, India, Cipla Ltd

First reported Feb 19 2013 - Updated Feb 20 2013 - 1 reports

GSK Pharma's consolidated EBDITA up by 5.7%, higher dividend of Rs.50 per share

GlaxoSmithKline Pharmaceuticals (GSK), a Rs.2,600 crore multinational pharma company, has posted satisfactory performance during the year ended December 2012 on account of lower exceptional items pertaining to rationalisation initiatives relating to a ... [Published PharmaBiz - Feb 19 2013]

Entities: Ambrisentan, Dividend, Pulmonary Arterial Hypertension

Quotes

"Ambrisentan was not effective in treating IPF and may be associated with an increased risk for disease progression and respiratory hospitalizations" the authors write

Ambrisentan not effective in idiopathic pulmonary fibrosis [Published Medical Xpress - May 08 2013]

...The author of an accompanying editorial writes that the research should prompt a discussion about "whether the current allocation system should be modified to limit access for candidates with unacceptably low predicted posttransplantation survival." A link to this article will go live at 5:00 p.m. on Monday, May 6. You may include this link in your article http://www.annals.org/article...

Annals of Internal Medicine tip sheet for May 7, 2013 [Published EurekAlert! - May 06 2013]

Raghu G, et al "TReatment of idiopathic pulmonary fibrosis with ambrisentan: A parallel, randomized trial" Ann Intern Med 2013; 158

Ambrisentan Fails in Lung Fibrosis [Published MedPage Today - May 06 2013]

Reacting to the criticism, DCGI G N Singh said the authorities were doing the best that was "humanly possible" at this time. "Within our constraints, we are doing our best. We have an honest approach and things will reach a logical conclusion in due course of time" he said

Parliamentary panel comes down hard on health ministry [Published Individual.com - Apr 27 2013]

More Content

sort by: Date \| Relevance
Drug Worsens Idiopathic Pulmonary Fibrosis [Published RT Magazine - May 15 2013]
A different kind of pressure [Published thestar.com.my - May 12 2013]
Pulmonary Arterial Hypertension [Published Advance for NPs and PAs - May 08 2013]
Gilead Sciences, Inc. (GILD): The Heart Of The ... [Published InsiderMonkey.com - May 08 2013]
Ambrisentan Fails in Lung Fibrosis [Published FDA News - May 08 2013]
Ambrisentan not effective in idiopathic pulmona... [Published Medical Xpress - May 08 2013]
Treatment of Idiopathic Pulmonary Fibrosis With... [Published Annals of Internal Medicine - May 07 2013]
Issue Summary May 7, 2013 [Published Annals of Internal Medicine - May 07 2013]
Annals of Internal Medicine tip sheet for May 7... [Published EurekAlert! - May 06 2013]
Ambrisentan Fails in Lung Fibrosis [Published MedPage Today - May 06 2013]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - May 03 2013]
United Therapeutic's Second PAH Stumble Emphasi... [Published Seeking Alpha - Apr 30 2013]
Parliamentary panel comes down hard on health m... [Published Individual.com - Apr 27 2013]
Pulmonary Arterial Hypertension (PAH) Therapeut... [Published PipelineReview - Apr 20 2013]
GSK Pharma's consolidated EBDITA up by 5.7%, hi... [Published PharmaBiz - Feb 19 2013]
GlaxoSmithKline net up by 11% to Rs. 164 cr [Published PharmaBiz - Aug 13 2012]